Boston Life Sciences, Inc. Adopts New Shareholder Rights Plan to Replace Expiring Plan.Business Editors BOSTON--(BUSINESS WIRE)--Sept. 13, 2001 Boston Life Sciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BLSI BLSI Boston Life Sciences, Inc. ) ("BLSI") announced that its Board of Directors has approved a new shareholder rights plan to replace BLSI's existing shareholder rights plan, which is expiring. Under the new plan new preferred stock purchase rights will be distributed to holders of record of BLSI's common stock. BLSI stated that the new rights plan, like the expiring rights plan, is designed to protect stockholders from attempts to acquire the company on terms or by using tactics that could deny all stockholders the opportunity to realize the full value of their investment and to assure the ability of BLSI's Board of Directors to protect stockholder interests. The Board of Directors may redeem the rights at a redemption price of $.01 per right, subject to adjustments to reflect any stock split, stock dividend, combination of shares or similar transaction, at any time prior to September 11, 2011, the expiration date of the rights. BLSI stated that the new rights plan was not adopted in response to any outside effort to gain control of the company, and that it is not aware of any takeover attempt. The rights will not affect BLSI's reported earnings (loss) per share. About Boston Life Sciences, Inc. BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder attention deficit hyperactivity disorder (ADHD), formerly called hyperkinesis or minimal brain dysfunction, a chronic, neurologically based syndrome characterized by any or all of three types of behavior: hyperactivity, distractibility, and impulsivity. (ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) Definition Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder characterized by distractibility, hyperactivity, impulsive behaviors, and the inability to remain focused on tasks or ) as well as treatments for cancer, autoimmune disease, and central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . BLSI's products in development include: ALTROPANE(TM) radioimaging agent for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine inosine /in·o·sine/ (I) (in´o-sen) a purine nucleoside containing the base hypoxanthine and the sugar ribose, which occurs in transfer RNAs and as an intermediate in the degradation of purines and purine nucleosides to uric acid and in , nerve growth factors for the treatment of acute and chronic CNS See Continuous net settlement. CNS See continuous net settlement (CNS). disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion